Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.76 USD
Change Today 0.00 / 0.00%
Volume 99.0K
ARQL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

arqule inc (ARQL) Snapshot

Open
$1.76
Previous Close
$1.76
Day High
$1.78
Day Low
$1.72
52 Week High
03/9/15 - $2.50
52 Week Low
10/15/14 - $1.04
Market Cap
110.7M
Average Volume 10 Days
163.7K
EPS TTM
$-0.29
Shares Outstanding
62.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARQULE INC (ARQL)

arqule inc (ARQL) Related Businessweek News

No Related Businessweek News Found

arqule inc (ARQL) Details

ArQule, Inc., a clinical-stage biotechnology company, researches and develops therapeutics for the treatment of cancer and rare diseases. Its lead product candidate is tivantinib, a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer and non-small cell lung cancer; Phase II clinical trial for the treatment of mesothelioma and kidney cancer; and Phase I clinical trial for the treatment of pediatric tumors, as well as has completed Phase II clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products in Phase Ib clinical trials include ARQ 092, an inhibitor of the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family for patients with cholangiocarcinoma and adrenocortical tumors, as well as with FGFR translocations, amplification, and mutations; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is used as a promoter of NQ01-mediated programmed cancer cell necrosis. Its pre-clinical development program also includes ARQ 751, a next-generation inhibitor of AKT. ArQule, Inc. has partnership agreement with Daiichi Sankyo Co., Ltd. to conduct research, clinical trials, and the commercialization of tivantinib for human cancer indications in the United States, Europe, South America, and internationally; and Kyowa Hakko Kirin Co., Ltd. to develop and commercialize tivantinib in Japan and parts of Asia. The company has collaboration agreement with the National Human Genome Research Institute of the NIH for a clinical trial investigating on ARQ 092, which is used for the treatment of Proteus syndrome. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.

36 Employees
Last Reported Date: 08/5/15
Founded in 1993

arqule inc (ARQL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $489.3K
President, Chief Operating Officer, General C...
Total Annual Compensation: $413.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $394.6K
Compensation as of Fiscal Year 2014.

arqule inc (ARQL) Key Developments

ArQule Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year 2015

ArQule Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $4,099,000 compared with $6,406,000 for the same period a year ago. Net loss was $4,017,000 or $0.06 per basic and diluted share compared with $6,339,000 or $0.10 per basic and diluted share for the same period a year ago. The company reported total revenues of $3,004,000 for the quarter ended June 30, 2015, compared with revenues of $2,901,000 for the quarter ended June 30, 2014. Revenue in the quarter ended June 30, 2015, is comprised of revenue from the Daiichi Sankyo tivantinib development agreement and the Kyowa Hakko Kirin exclusive license agreement for tivantinib. The $0.1 million revenue increase for the quarter ended June 30, 2015 is due to higher revenue from the Daiichi Sankyo tivantinib program. For the six months, the company reported loss from operations of $8,914,000 compared with $13,711,000 for the same period a year ago. Net loss was $8,568,000 or $0.14 per basic and diluted share compared with $13,480,000 or $0.22 per basic and diluted share for the same period a year ago. Revenues for the six months ended June 2015, were $5,789,000 compared with revenues of $5,577,000 for the 6 months ended June 30, 2014. Revenue in the six months ended June 30, 2015, is comprised of revenue from the Daiichi Sankyo tivantinib development agreement and the Kyowa Hakko Kirin exclusive license agreement for tivantinib. The increase of $0.2 million in the six months ended June 30, 2015, is due to higher revenue from the Daiichi Sankyo tivantinib program. For 2015, the company expects net use of cash to range between $26 million and $29 million, revenue is expected to range between $8 million and $10 million, net loss is expected to range between $18 million and $21 million and net loss per share is to range between $0.29 and $0.33 loss for the year.

ArQule Inc. to Report Q2, 2015 Results on Aug 05, 2015

ArQule Inc. announced that they will report Q2, 2015 results at 9:00 AM, US Eastern Standard Time on Aug 05, 2015

ArQule Inc., Q2 2015 Earnings Call, Aug 05, 2015

ArQule Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARQL:US $1.76 USD 0.00

ARQL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AVEO Pharmaceuticals Inc $1.42 USD +0.02
CrystalGenomics Inc 13,400 KRW +400.00
Curis Inc $2.59 USD +0.09
Cytokinetics Inc $7.00 USD +0.22
Rigel Pharmaceuticals Inc $2.99 USD +0.12
View Industry Companies
 

Industry Analysis

ARQL

Industry Average

Valuation ARQL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.6x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARQULE INC, please visit www.arqule.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.